entertainment -WSS

entertainment

author：entertainment 2025-09-30 18:54:06 - browse：1

Alnylam headquarters — Kristoffer Tripplaar/Sipa USA/AP

A group of advisers to the Food and Drug Administration voted in favor of Alnylam Pharmaceuticals’ treatment for a debilitating heart disease Wednesday, but only after a day-long debate challenging whether the drug’s modest observed effects were actually meaningful for patients.

The group of independent experts voted 9-3 that the benefits of Alnylam’s drug, called patisiran, outweighed its risks for patients with ATTR-CM, a progressive disease that leads to fatal heart failure if left untreated. The FDA, which is not required to follow the advice of advisers, is expected to make a final decision on patisiran by Oct. 8.

“It’s like a light wind blowing in favor of patisiran over placebo,” said David Cella, a neurologist at the Northwestern University Feinberg School of Medicine who voted in favor of patisiran. David Moliterno, a cardiologist at the University of Kentucky, added that “the good news in this story is that while there may be a small benefit, it doesn’t look like there’s a signal for harm.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： SAMSHA loosens regulations on methadone treatment centers

WSS

Time to name cancers by genetics, not organ of origin, expert says

Thousands protest mob assault of women who were paraded naked in remote Indian border state

Readout Newsletter: Vertex, Biogen's Aduhelm, and Bristol updates

Weekend shootings leave at least 6 dead, 20 others wounded in Chicago

Thousands protest mob assault of women who were paraded naked in remote Indian border state

The real point of Kenneth Smith’s execution by nitrogen gas

Wikipedia

entertainment

hotspot

At least 13 dead in Texas as scorching temps continue

General Catalyst, Summa Health deal will turn on physician buy

Jerome Adams on the need for new antivirals for Covid

FDA drug safety: Singulair case shows systemic surveillance flaws

Peter Hotez and the public health issue of online harassment

Covid misinformation case heads to Supreme Court

Apple is now the first public company to be valued at $3 trillion

Mike Pence ‘not interested in trading insults’ with Trump as he tries to win New Hampshire

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Readout Newsletter: Vertex, Biogen's Aduhelm, and Bristol updates

knowledge

Cognito secures funding to test medical device for Alzheimer's

FDA approves first blood sugar monitor without finger pricks

Thousands protest mob assault of women who were paraded naked in remote Indian border state

Time to name cancers by genetics, not organ of origin, expert says

Some dementia cases could be undiagnosed liver disease

Congressmen charge Covid hearing ‘could have been an email’

hotspot

knowledge

focus

hotspot